Literature DB >> 20402194

The occurrence of rare cancers in U.S. adults, 1995-2004.

Robert T Greenlee1, Marc T Goodman, Charles F Lynch, Charles E Platz, Lori A Havener, Holly L Howe.   

Abstract

OBJECTIVE: Rare cancers have been traditionally understudied, reducing the progress of research and hindering decisions for patients, physicians, and policy makers. We evaluated the descriptive epidemiology of rare cancers using a large, representative, population-based dataset from cancer registries in the United States.
METHODS: We analyzed more than 9 million adult cancers diagnosed from 1995 to 2004 in 39 states and two metropolitan areas using the Cancer in North America (CINA) dataset, which covers approximately 80% of the U.S. population. We applied an accepted cancer classification scheme and a published definition of rare (i.e., fewer than 15 cases per 100,000 per year). We calculated age-adjusted incidence rates and rare/non-rare incidence rate ratios using SEER*Stat software, with analyses stratified by gender, age, race/ethnicity, and histology.
RESULTS: Sixty of 71 cancer types were rare, accounting for 25% of all adult tumors. Rare cancers occurred with greater relative frequency among those who were younger, nonwhite, and of Hispanic ethnicity than among their older, white, or non-Hispanic counterparts.
CONCLUSIONS: Collectively, rare tumors account for a sizable portion of adult cancers, and disproportionately affect some demographic groups. Maturing population-based cancer surveillance data can be an important source for research on rare cancers, potentially leading to a greater understanding of these cancers and eventually to improved treatment, control, and prevention.

Entities:  

Mesh:

Year:  2010        PMID: 20402194      PMCID: PMC2789814          DOI: 10.1177/003335491012500106

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  32 in total

1.  Rare cancers.

Authors:  T Joannides
Journal:  Clin Oncol (R Coll Radiol)       Date:  2001       Impact factor: 4.126

2.  Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998.

Authors:  Margaret E McCusker; Timothy R Coté; Limin X Clegg; Leslie H Sobin
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

3.  Long-term outcomes of malignant phyllodes tumors patients: an institutional experience.

Authors:  Adora Fou; Freya R Schnabel; Diane Hamele-Bena; Xiao-Jun Wei; Bin Cheng; Mahmoud El Tamer; Laura Klein; Kathie Ann Joseph
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

4.  [Disease registries in the epidemiological researching of rare diseases in Spain].

Authors:  Oscar Zurriaga Lloréns; Carmen Martínez García; Vanessa Arizo Luque; Maria José Sánchez Pérez; Julián Mauro Ramos Aceitero; Maria José García Blasco; Maria José Ferrari Arroyo; Lilisbeth Perestelo Peréz; Enrique Ramalle Gómara; Maria Luisa Martínez Frías; Manuel Posada de la Paz
Journal:  Rev Esp Salud Publica       Date:  2006 May-Jun

5.  Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases.

Authors:  Sanziana Roman; Rong Lin; Julie Ann Sosa
Journal:  Cancer       Date:  2006-11-01       Impact factor: 6.860

6.  Incidence of noncutaneous melanomas in the U.S.

Authors:  Colleen C McLaughlin; Xiao-Cheng Wu; Ahmedin Jemal; Howard J Martin; Lisa M Roche; Vivien W Chen
Journal:  Cancer       Date:  2005-03-01       Impact factor: 6.860

7.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

Authors:  Lindsay M Morton; Jennifer J Turner; James R Cerhan; Martha S Linet; Patrick A Treseler; Christina A Clarke; Andrew Jack; Wendy Cozen; Marc Maynadié; John J Spinelli; Adele Seniori Costantini; Thomas Rüdiger; Aldo Scarpa; Tongzhang Zheng; Dennis D Weisenburger
Journal:  Blood       Date:  2007-03-27       Impact factor: 22.113

8.  Measures of racial/ethnic health disparities in cancer mortality rates and the influence of socioeconomic status.

Authors:  Kenneth C Chu; Barry A Miller; Sanya A Springfield
Journal:  J Natl Med Assoc       Date:  2007-10       Impact factor: 1.798

9.  Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002.

Authors:  Jennifer F Yamamoto; Marc T Goodman
Journal:  Cancer Causes Control       Date:  2007-12-07       Impact factor: 2.506

10.  Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium.

Authors:  Anne Kricker; Bruce K Armstrong; Ann Maree Hughes; Chris Goumas; Karin Ekström Smedby; Tongzhang Zheng; John J Spinelli; Sylvia De Sanjosé; Patricia Hartge; Mads Melbye; Eleanor V Willett; Nikolaus Becker; Brian C H Chiu; James R Cerhan; Marc Maynadié; Anthony Staines; Pierluigi Cocco; Paolo Boffeta
Journal:  Int J Cancer       Date:  2008-01-01       Impact factor: 7.396

View more
  34 in total

1.  Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Authors:  Roman Groisberg; David S Hong; Jason Roszik; Filip Janku; Apostolia M Tsimberidou; Milind Javle; Funda Meric-Bernstam; Vivek Subbiah
Journal:  Mol Cancer Ther       Date:  2018-04-13       Impact factor: 6.261

2.  Solitary-fibrous tumor/hemangiopericytoma of the central nervous system: a population-based study.

Authors:  Connor J Kinslow; Samuel S Bruce; Ali I Rae; Sameer A Sheth; Guy M McKhann; Michael B Sisti; Jeffrey N Bruce; Adam M Sonabend; Tony J C Wang
Journal:  J Neurooncol       Date:  2018-02-09       Impact factor: 4.130

3.  The Spectrum of Caregiving in Palliative Care for Serious, Advanced, Rare Diseases: Key Issues and Research Directions.

Authors:  Lynn S Adams; Jeri L Miller; Patricia A Grady
Journal:  J Palliat Med       Date:  2016-06-01       Impact factor: 2.947

Review 4.  The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Authors:  Anne F Schott; John J Welch; Claire F Verschraegen; Razelle Kurzrock
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

Review 5.  Emerging Opportunities for Target Discovery in Rare Cancers.

Authors:  Tanaz Sharifnia; Andrew L Hong; Corrie A Painter; Jesse S Boehm
Journal:  Cell Chem Biol       Date:  2017-09-21       Impact factor: 8.116

6.  Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours.

Authors:  A F Leary; M Quinn; K Fujiwara; R L Coleman; E Kohn; T Sugiyama; R Glasspool; I Ray-Coquard; N Colombo; M Bacon; A Zeimet; A Westermann; E Gomez-Garcia; D Provencher; S Welch; W Small; D Millan; A Okamoto; G Stuart; K Ochiai
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

7.  Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Authors:  Shumei Kato; Nithya Krishnamurthy; Kimberly C Banks; Pradip De; Kirstin Williams; Casey Williams; Brian Leyland-Jones; Scott M Lippman; Richard B Lanman; Razelle Kurzrock
Journal:  Cancer Res       Date:  2017-06-22       Impact factor: 12.701

Review 8.  Targeted therapy in rare cancers--adopting the orphans.

Authors:  Javier Munoz; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2012-09-11       Impact factor: 66.675

Review 9.  What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report.

Authors:  Monica M Bertagnolli; Charles D Blanke; Walter J Curran; Douglas S Hawkins; Robert S Mannel; Peter J O'Dwyer; Mitchell D Schnall; Norman Wolmark
Journal:  Cancer       Date:  2020-09-24       Impact factor: 6.860

10.  Developing therapies for rare tumors: opportunities, challenges and progress.

Authors:  Diana Bradford; Karlyne M Reilly; Brigitte C Widemann; Abby Sandler; Shivaani Kummar
Journal:  Expert Opin Orphan Drugs       Date:  2015-12-09       Impact factor: 0.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.